Prediction of Prognosis, Efficacy of Lung Adenocarcinoma by Machine Learning Model Based on Immune and Metabolic Related Genes

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 18

PMID 39692796

Authors

Cong Xue

Yi-Zhi Dai

Gui-Long Li

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study is to integrate immune and metabolism-related genes in order to construct a predictive model for predicting the prognosis and treatment response of LUAD(lung adenocarcinoma) patients, aiming to address the challenges posed by this highly lethal and heterogeneous disease.

Material And Methods: Using TCGA-LUAD as the training subset, differential gene expression analysis, batch survival analysis, Lasso regression analysis, univariate and multivariate Cox regression analysis were performed to construct prognostic related gene models. GEO queue as validation subsets, is used to validate build Riskscore. Then, we explore the Riskscore and mutation status, immune cell infiltration, the relationship between immune therapy and chemotherapy, and build the model of the nomogram.

Results: The Riskscore has been determined to be composed of seven gene. In the high-risk group defined by this score, both early-stage and advanced-stage LUAD patients exhibit a decreased overall survival rate. The mutation status of patients as well as immune cell infiltration show associations with the Riskscore value obtained from these genes' expression levels. Furthermore, there exist variations in response to immunotherapy as well as sensitivity to commonly used chemotherapy drugs among different individuals. Lastly, when using a column line plot model based on the calculated Riskscore values, we obtain a concordance index (C-index) was 0 .716 (95% CI 0.671-0.762), and time-dependent ROC predicted probabilities of 1-, 3- and 5-year survival for LUAD patients were 0.752, 0.725 and 0.654, respectively.

Conclusion: In conclusion, we have successfully developed a predictive model incorporating immune and metabolism-related genes, encompassing gene expression levels of CAT/CCL20/GPI/INSL4 NT5E/GSTA3/GNPNAT1. This comprehensive model not only enables the prognosis prediction for LUAD patients but also facilitates the prediction of their response to first-line chemotherapy drugs and immune checkpoint inhibitors, thus demonstrating its broad potential in clinical applications. However, our study still has limitations as it is based on TCGA and GEO databases with limited pathological characteristics of patients. Therefore, more practical and valuable factors are needed to predict efficacy. The crosstalk between metabolism and immunity remains to be explored. Finally, this study lacks experimental evidence for the underlying gene expression of prognosis and further research is required.

References

Wu S, Liu B, Ai Z, Hong Z, You P, Wu H . Esculetin Inhibits Cancer Cell Glycolysis by Binding Tumor PGK2, GPD2, and GPI. Front Pharmacol. 2020; 11:379. PMC: 7118906. DOI: 10.3389/fphar.2020.00379. View

Zhang H, Cao Y, Tang J, Wang R . CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway. Biomed Res Int. 2022; 2022:9944847. PMC: 9259339. DOI: 10.1155/2022/9944847. View

Martinez-Reyes I, Chandel N . Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680. DOI: 10.1038/s41568-021-00378-6. View

Wang Y, Wang Y, Ren Y, Zhang Q, Yi P, Cheng C . Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Semin Cancer Biol. 2022; 86(Pt 3):542-565. DOI: 10.1016/j.semcancer.2022.02.010. View

Gentric G, Mieulet V, Mechta-Grigoriou F . Heterogeneity in Cancer Metabolism: New Concepts in an Old Field. Antioxid Redox Signal. 2016; 26(9):462-485. PMC: 5359687. DOI: 10.1089/ars.2016.6750. View

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View

Li V, Li K, Li J . TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. J Cancer Res Clin Oncol. 2018; 145(3):625-636. DOI: 10.1007/s00432-018-2817-z. View

Wu T, Liu Y, Cao Y, Liu Z . Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma. Adv Mater. 2022; 34(15):e2110364. DOI: 10.1002/adma.202110364. View

Wei W, Zhao X, Zhu J, Zhang L, Chen Y, Zhang B . lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling. Oncol Rep. 2019; 42(5):1946-1956. PMC: 6775802. DOI: 10.3892/or.2019.7302. View

10.

Liu C, Hu F, Xia M, Han L, Zhang Q, Guo A . GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018; 34(21):3771-3772. DOI: 10.1093/bioinformatics/bty411. View

11.

Zhu M, Zeng Q, Fan T, Lei Y, Wang F, Zheng S . Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. Front Immunol. 2022; 13:783495. PMC: 8867215. DOI: 10.3389/fimmu.2022.783495. View

12.

Luanpitpong S, Angsutararux P, Samart P, Chanthra N, Chanvorachote P, Issaragrisil S . Hyper-O-GlcNAcylation induces cisplatin resistance via regulation of p53 and c-Myc in human lung carcinoma. Sci Rep. 2017; 7(1):10607. PMC: 5587763. DOI: 10.1038/s41598-017-10886-x. View

13.

Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M . PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. J Thorac Oncol. 2018; 13(8):1113-1120. DOI: 10.1016/j.jtho.2018.04.017. View

14.

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

15.

Klonisch T, Bialek J, Radestock Y, Hoang-Vu C, Hombach-Klonisch S . Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. Adv Exp Med Biol. 2007; 612:104-18. DOI: 10.1007/978-0-387-74672-2_8. View

16.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

17.

Kadomoto S, Izumi K, Mizokami A . The CCL20-CCR6 Axis in Cancer Progression. Int J Mol Sci. 2020; 21(15). PMC: 7432448. DOI: 10.3390/ijms21155186. View

18.

Funasaka T, Hu H, Hogan V, Raz A . Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence. J Biol Chem. 2007; 282(50):36362-9. DOI: 10.1074/jbc.M706301200. View

19.

Biswas S . Metabolic Reprogramming of Immune Cells in Cancer Progression. Immunity. 2015; 43(3):435-49. DOI: 10.1016/j.immuni.2015.09.001. View

20.

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View